Evidence map›Paper›PMID 37434164›Full record

ArticleLipids in health and disease2023

Low-grade inflammation is associated with a heterogeneous lipoprotein subclass profile in an apparently healthy population sample.

Daniel L Pontzen, Martin Bahls, Diana Albrecht, Stephan B Felix, Marcus Dörr, Till Ittermann, Matthias Nauck, Nele Friedrich

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Daniel L PontzenUniversity Medicine Greifswald, Ferdinand-Sauerbruch-Str. 17475, Greifswald, Germany.
Martin BahlsUniversity Medicine Greifswald, Ferdinand-Sauerbruch-Str. 17475, Greifswald, Germany. martin.bahls@uni-greifswald.de.
Diana AlbrechtInstitute for Community Medicine, SHIP-KEF, University Medicine Greifswald, Greifswald, Germany.
Stephan B FelixUniversity Medicine Greifswald, Ferdinand-Sauerbruch-Str. 17475, Greifswald, Germany.
Marcus DörrUniversity Medicine Greifswald, Ferdinand-Sauerbruch-Str. 17475, Greifswald, Germany.
Till IttermannGerman Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany.
Matthias NauckGerman Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany.
Nele FriedrichGerman Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany.
Universitätsmedizin Greifswald · DEGerman Centre for Cardiovascular Research · DELeibniz Institute for Plasma Science and Technology · DE

Funding

Bundesministerium für Bildung und Forschung 01ZZ0403Deutsches Zentrum für Herz-Kreislaufforschung 81Z0400101
6 · The paper itself

Abstract

BACKGROUND AND

aimsPrevention measures for cardiovascular diseases (CVD) have shifted their focus from lipoproteins to the immune system. However, low-grade inflammation and dyslipidemia are tightly entangled. The objective of this study was to assess the relations between a broad panel of inflammatory biomarkers and lipoprotein subclass parameters.

methodsWe utilized data from the population-based Study of Health in Pomerania (SHIP-TREND, n = 403). Plasma concentrations of 37 inflammatory markers were measured by a bead-based assay. Furthermore, we employed nuclear magnetic resonance spectroscopy to measure total cholesterol, total triglycerides, total phospholipids as well as the fractional concentrations of cholesterol, triglycerides, phospholipids, ApoA1, ApoA2 and ApoB in all major lipoprotein subclasses. Associations between inflammatory biomarkers and lipoprotein subclasses were analyzed by adjusted linear regression models.

resultsAPRIL, BAFF, TWEAK, sCD30, Pentraxin-3, sTNFR1, sTNFR2, Osteocalcin, Chitinase 3-like 1, IFN-alpha2, IFN-gamma, IL-11, IL-12p40, IL-29, IL-32, IL-35, TSLP, MMP1 and MMP2 were related with lipoprotein subclass components, forming two distinct clusters. APRIL had inverse relations to HDL-C (total and subclasses) and HDL Apo-A1 and Apo-A2 content. MMP-2 was inversely related to VLDL-C (total and subclasses), IDL-C as well as LDL5/6-C and VLDL-TG, IDL-TG, total triglycerides as well as LDL5/5-TG and HDL4-TG. Additionally, we identified a cluster of cytokines linked to the Th1-immune response, which were associated with an atherogenic lipoprotein profile.

conclusionOur findings expand the existing knowledge of inflammation-lipoprotein interactions, many of which are suggested to be involved in the pathogeneses of chronic non-communicable diseases. The results of our study support the use of immunomodulatory substances for the treatment and possibly prevention of CVD.

Indexed as

Cardiovascular DiseasesInflammationApolipoprotein A-IIApolipoproteins BCytokinesHumansApolipoprotein A-IIApolipoproteins BCytokinesApolipoprotein concentrationCardiovascular diseaseChronic non-communicable diseasesCytokinesDyslipidemiaEnergy mobilizationEpidemiologyGelatinase AHDLHeart-liver axisImmunometabolismInflammationInflammatory biomarkersLDLLipid metabolismLipidomicsLipolysisLipoprotein particlesLipoprotein subclassesMMP2Nuclear magnetic resonance spectroscopyPrevention of cardiovascular diseasesPrevention of metabolic diseasesResidual riskSmall dense LDLSoluble APRILSoluble BAFFTNFVLDL

Identifiers

PMID37434164
PMCPMC10334607
OpenAlexW4383908725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.